International Cannabis Weekly: 161
- Will cannabis help in the fight against COVID-19? Prohibition Partners dive deeper.
- US cannabis companies outperform Canada in Q2 2020 earnings.
- Federal court denies DEA’s request to dismiss cannabis rescheduling case.
- Canada is accused of protectionism by blocking cannabis imports, as exports rise.
- Cansativa receives four-year contract for German-produced medical cannabis.
- UK family seeks judicial review of NHS guidelines for the prescription of cannabis oil.
- EMMAC secures GDP licence for the distribution of medicinal cannabis in Switzerland.
- The French National Medicines Agency plans to authorise hemp flowers and leaves.
- Shareholders of Sativa Group vote in favour of Stillcanna acquisition.
- Tilray is recalling its cannabis extract again in Germany.
- Different interpretations of tax law in Poland give competitive advantage.
The Impact Series: Disrupting Drinks details the result of Prohibition Partners’ unique consumer research polling, covering over 15,000 adults across seven-country markets evaluating usage, purchase and attitudes towards cannabinoid-based products.
Our analysis also includes an investigation into the latest developments across global regulations and legislation, providing clarity for investors, operators and market entrants.
- Money managers are investing in cannabis stocks ahead of US elections.
- State treasurers seek cannabis banking reform in next COVID-19 relief package.
- Texas judge temporarily lifts the ban on selling smokable hemp products.
- Maine will commence retail sales of adult-use cannabis on 9 October.
- Vermont lawmakers announce they are finalising a bill to legalise cannabis sales.
- Top law-enforcement officials publicly urge Congress to decriminalise cannabis.
- Dutchie, a cannabis e-commerce platform, completes Series B funding round.
- Florida-based REIT raises US$80 million in capital to lend to cannabis operators.
- Curaleaf reports an increase of 22% in total revenue in Q2 2020 results.
- Canadian inventory of cannabis edibles and beverages dramatically outpaces sales.
- Aphria plans to acquire non-cannabis US brands to build out cannabis capabilities.
- Canadian cannabis companies tackle illicit markets with competitive prices.
- Avicanna reports an increase of 172% in revenue in Q2 2020 results.
- Adastra announces supply agreement of cannabis biomass with Pure Sunfarms.
Latam & Caribbean
- Mexico’s president maintains there will be legal reform for the regulation of cannabis.
- Cplant seeks to raise US$10 million to fund cannabis retail expansion.
- Uruguay’s cannabis companies estimate medical exports will reach US$1 billion.
- Argentina’s federal court no longer considers cannabis as a narcotic.
- New Zealand delays general election and cannabis referendum by a month.
- Rua Bioscience get commercial licence for cannabis-derived medicines & plans IPO.
- MediPharm receives licence to manufacture API derived from cannabis in Australia.
- Cannatrek receives medical cannabis shipment from Clever Leaves.
- MGC Pharmaceuticals releases results for treatment of COVID-19.
- Cann Group share purchase plan (SSP) oversubscribed by $10m.
The Disrupting Drinks Report
The link between COVID-19 and cannabis may seem tenuous, but what if there is a serious potential for the plant to become a global solution? Read the full analysis from Prohibition Partners, here.
On the global cannabis industry
International Cannabis Weekly newsletter brings you the most important developments, news and informed commentary on the global cannabis industry. Join our community of 70,000+ subscribers.